AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14601763 — intervention group
Group type: EXPERIMENTAL
Intervention: SCPRTs
Number of subjects: 0
Study 10974295 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (3‐day course, oral dose of 10 mg/kg per day)
Number of subjects: 96
Study 10974295 — intervention group
Group type: COMPARATOR
Intervention: Topical oxytetracycline/polymyxin ointment (twice a day for 2 months)
Number of subjects: 96
Study 8792795 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of usual treatment (methotrexate, penicillamine, or sulfasalazine)
Number of subjects: 112
Study 8792795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 1621750 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (200 mg capsules twice a day or 15 mg/kg/day suspension)
Number of subjects: 107
Study 1621750 — intervention group
Group type: COMPARATOR
Intervention: Penicillin VK (250 mg capsules four times a day or 20 mg/kg/day suspension)
Number of subjects: 107
Study 1621750 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 107
Study 1621750 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 107
Study 7113952 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (mild) increasing daily expenditure to 110% of sedentary expenditure
Number of subjects: 6
Study 7113952 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (moderate) increasing daily expenditure to 125% of sedentary expenditure
Number of subjects: 6
Study 7113952 — intervention group
Group type: COMPARATOR
Intervention: Sedentary treatment
Number of subjects: 6
Study 31734761 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond 1064-nm Nd:YAG laser (Pico-arm)
Number of subjects: 25
Study 31734761 — intervention group
Group type: COMPARATOR
Intervention: Quasi-long-pulsed 1064-nm Nd:YAG laser (Quasi-arm)
Number of subjects: 25
Study 31734761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment score (Pico-arm)
Number of subjects: 25
Study 31734761 — intervention group
Group type: COMPARATOR
Intervention: Pain assessment score (Quasi-arm)
Number of subjects: 25
Study 31475793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban monotherapy
Number of subjects: 2236
Study 31475793 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with rivaroxaban plus a single antiplatelet agent
Number of subjects: 2236
Study 27775865 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus low-dose tacrolimus (EVR+LTac)
Number of subjects: 100
Study 25895054 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive neurostimulator system (RNS System) for detecting ECoG events
Number of subjects: 128
Study 23437144 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 µg calcitriol per day
Number of subjects: 27
Study 23437144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 22128042 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 320
Study 22128042 — intervention group
Group type: COMPARATOR
Intervention: Usual care and attention control conditions
Number of subjects: 320
Study 19150743 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized light breakfast (SLB) in adults with glucose intolerance (AD-GI)
Number of subjects: 32
Study 19150743 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized light breakfast (SLB) in adults without glucose intolerance (AD-GT)
Number of subjects: 32
Study 19150743 — intervention group
Group type: COMPARATOR
Intervention: Fasting AG and AG/TG ratio in adults with glucose intolerance (AD-GI)
Number of subjects: 32
Study 19150743 — intervention group
Group type: COMPARATOR
Intervention: Fasting TG and AG
Number of subjects: 32
Study 19150743 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-SLB AG
Number of subjects: 32
Study 17183010 — intervention group
Group type: EXPERIMENTAL
Intervention: School providing information on sex
Number of subjects: 0
Study 17183010 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy communication with parent or guardian at baseline
Number of subjects: 0
Study 17183010 — intervention group
Group type: COMPARATOR
Intervention: Low sexual health knowledge
Number of subjects: 0
Study 15236979 — intervention group
Group type: EXPERIMENTAL
Intervention: Short hCG-IUI interval (32-34 hours)
Number of subjects: 189
Study 15236979 — intervention group
Group type: COMPARATOR
Intervention: Long hCG-IUI interval (38-40 hours)
Number of subjects: 189
Study 12153554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with ursodeoxycholic acid (500 mg bid) and pravastatin (20 mg bid) for three weeks before cholecystectomy
Number of subjects: 19
Study 12153554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid only
Number of subjects: 19
Study 12153554 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 19
Study 12153554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with ursodeoxycholic acid and pravastatin
Number of subjects: 19
Study 9817157 — intervention group
Group type: EXPERIMENTAL
Intervention: Current peak expiratory flow (PEF) criteria
Number of subjects: 133
Study 9817157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharpened cut-off values and time- and treatment-specific PEFs
Number of subjects: 133
Study 9817157 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning peak expiratory flow before any (bronchodilator) treatment
Number of subjects: 133
Study 7543891 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose rate (HDR) conformal boost brachytherapy with 45.6 Gy whole pelvis external irradiation and three HDR fractions of 5.5 Gy each (18 patients) or 6 Gy each (15 patients) to the prostate.
Number of subjects: 33
Study 2708231 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lipopolysaccharides (LPS) from Escherichia coli 026:B6 (22.2-micrograms total dose)
Number of subjects: 14
Study 2708231 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure (diluent substituted for LPS solution)
Number of subjects: 14
Study 322922 — intervention group
Group type: COMPARATOR
Intervention: N-acetylprocainamide (NAPA)
Number of subjects: 10
Study 31635952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough management algorithm
Number of subjects: 115
Study 31635952 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 115
Study 28218605 — intervention group
Group type: EXPERIMENTAL
Intervention: GSS6Fr (6 Fr Glidesheath Slender)
Number of subjects: 1926
Study 28218605 — intervention group
Group type: COMPARATOR
Intervention: GS5Fr (standard 5 Fr sheath)
Number of subjects: 1926
Study 28218605 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent haemostasis
Number of subjects: 1926
Study 28218605 — intervention group
Group type: COMPARATOR
Intervention: Institutional haemostasis
Number of subjects: 1926
Study 28218605 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints (vascular access-site complications, local bleeding, spasm)
Number of subjects: 1926
Study 24833003 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal blood glucose management (BGM) (120-180 mg/dl)
Number of subjects: 846
Study 24833003 — intervention group
Group type: COMPARATOR
Intervention: Strict blood glucose management (BGM) (90-110 mg/dl)
Number of subjects: 846
Study 23829604 — intervention group
Group type: COMPARATOR
Intervention: Elite female football players (ET)
Number of subjects: 55
Study 23829604 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained young women (UT) after 16 weeks of football training
Number of subjects: 55
Study 21771085 — intervention group
Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS mixture (8 g/l)
Number of subjects: 74
Study 21771085 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 74
Study 18706874 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD (defined as heartburn and/or regurgitation of any frequency during the 1-week recall period of the RDQ)
Number of subjects: 1200
Study 18706874 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD
Number of subjects: 1200
Study 17196507 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day finasteride
Number of subjects: 355
Study 17196507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 15234686 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal subjects (no TMJ-ID)
Number of subjects: 6
Study 15234686 — intervention group
Group type: COMPARATOR
Intervention: TMJ-ID subjects (with anterior disc displacement)
Number of subjects: 6
Study 12127031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling with 8 degrees C for 30 min on the burn
Number of subjects: 24
Study 12127031 — intervention group
Group type: COMPARATOR
Intervention: Non-active dummy on the control burn
Number of subjects: 24
Study 9747475 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials in rhinology
Number of subjects: 0
Study 9747475 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials in head and neck oncology
Number of subjects: 0
Study 9747475 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall RCTs assessed
Number of subjects: 0
Study 9747475 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of trials
Number of subjects: 0
Study 9747475 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of RCTs in ENT literature
Number of subjects: 0
Study 7966789 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy with M‐VAC or M‐VEC
Number of subjects: 83
Study 7966789 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant M‐VAC/M‐VEC
Number of subjects: 83
Study 7966789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment)
Number of subjects: 83
Study 2752698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyazide (triamterene 50 mg and hydrochlorothiazide 25 mg)
Number of subjects: 30
Study 2752698 — intervention group
Group type: COMPARATOR
Intervention: Generic triamterene-hydrochlorothiazide product
Number of subjects: 30
Study 331919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate (1200 mg daily) plus amitriptyline
Number of subjects: 0
Study 331919 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus amitriptyline
Number of subjects: 0
Study 331919 — intervention group
Group type: COMPARATOR
Intervention: Neither placebo nor cyclandelate
Number of subjects: 0
Study 331919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31475391 — intervention group
Group type: EXPERIMENTAL
Intervention: NBO education programme
Number of subjects: 111
Study 31475391 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NBO education)
Number of subjects: 111
Study 29553435 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration salts plus Zn sulphate (10 mg for children younger than 6 months; 20 mg for children aged 6 months and older)
Number of subjects: 140
Study 29553435 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration salts plus Zn sulphate
Number of subjects: 140
Study 29553435 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration salts
Number of subjects: 140
Study 27439082 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention: structured moderate-intensity program, predominantly walking 2 times per week for 2.6 years on average.
Number of subjects: 1635
Study 27439082 — intervention group
Group type: COMPARATOR
Intervention: Successful aging intervention: weekly health education sessions for 6 months, then monthly.
Number of subjects: 1635
Study 27439082 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1635
Study 27439082 — intervention group
Group type: COMPARATOR
Intervention: Successful aging intervention
Number of subjects: 1635
Study 27439082 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention among frailer participants (SPPB < 8)
Number of subjects: 1635
Study 27439082 — intervention group
Group type: COMPARATOR
Intervention: Successful aging intervention among frailer participants (SPPB < 8)
Number of subjects: 1635
Study 27439082 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention among participants with SPPB score of 8 or 9
Number of subjects: 1635
Study 27439082 — intervention group
Group type: COMPARATOR
Intervention: Successful aging intervention among participants with SPPB score of 8 or 9
Number of subjects: 1635
Study 25234181 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 Fr nasobiliary catheter
Number of subjects: 100
Study 25234181 — intervention group
Group type: COMPARATOR
Intervention: 5 Fr nasobiliary catheter
Number of subjects: 100
Study 22791092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal lucinactant (175 mg/kg)
Number of subjects: 165
Study 22791092 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 165
Study 20976802 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using hexylaminolevulinate (HAL) and methylaminolevulinate (MAL)
Number of subjects: 25
Study 17359604 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite impermeable bed covers and self-management plan
Number of subjects: 126
Study 17359604 — intervention group
Group type: COMPARATOR
Intervention: Placebo bed covers and self-management plan
Number of subjects: 126
Study 15791112 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (M6G)
Number of subjects: 100
Study 15791112 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 100
Study 12060470 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic analysis using a* and L* values from reflectance spectrometer measurements.
Number of subjects: 0
Study 12060470 — intervention group
Group type: COMPARATOR
Intervention: Control group of adjacent normal skin for comparison.
Number of subjects: 0
Study 9952252 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality disordered group
Number of subjects: 39
Study 7673693 — intervention group
Group type: COMPARATOR
Intervention: UVC clothing
Number of subjects: 0
Study 7673693 — intervention group
Group type: COMPARATOR
Intervention: UVC at 100 microW cm‐2 s‐1
Number of subjects: 0
Study 7673693 — intervention group
Group type: COMPARATOR
Intervention: UVC at 300 microW cm‐2 s‐1
Number of subjects: 0
Study 7673693 — intervention group
Group type: COMPARATOR
Intervention: Filtered vertical laminar flow
Number of subjects: 0
Study 2192454 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 500 mg dimethylpolysiloxane (DPS)/24 hours
Number of subjects: 13
Study 2192454 — intervention group
Group type: COMPARATOR
Intervention: 2 x 500 mg dimethylpolysiloxane (DPS)/12 hours
Number of subjects: 13
Study 402831 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound scanning
Number of subjects: 3000
Study 402831 — intervention group
Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 3000
Study 402831 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements in limbs, fluorescence and radioisotope clearance studies
Number of subjects: 3000
Study 29746263 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty Management Program (UMP)
Number of subjects: 115
Study 29746263 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 115
Study 28653424 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of anesthetic ointment (lidocaine/prilocaine‐AO)
Number of subjects: 444
Study 24866348 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion
Number of subjects: 25
Study 23246114 — intervention group
Group type: EXPERIMENTAL
Intervention: Satinsky clamps
Number of subjects: 120
Study 23246114 — intervention group
Group type: COMPARATOR
Intervention: Tourniquets
Number of subjects: 120
Study 22185749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.4 mg/mL applied intraoperatively for 5 minutes
Number of subjects: 30
Study 22185749 — intervention group
Group type: COMPARATOR
Intervention: No Mitomycin C (Control)
Number of subjects: 30
Study 22185749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 30
Study 19821717 — intervention group
Group type: EXPERIMENTAL
Intervention: Haishengsu (2.4 mg, intravenously for 15 days)
Number of subjects: 55
Study 16968347 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone (50 mg/day)
Number of subjects: 169
Study 16968347 — intervention group
Group type: EXPERIMENTAL
Intervention: acamprosate (1998 mg/day)
Number of subjects: 169
Study 16968347 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 169
Study 15562654 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: prefabricated glass‐fiber posts and Artglass polymer core
Number of subjects: 42
Study 15562654 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: prefabricated glass‐fiber posts and Charisma composite resin core
Number of subjects: 42
Study 15562654 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: prefabricated glass‐fiber posts and AB composite resin core
Number of subjects: 42
Study 11131368 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried onions meal
Number of subjects: 6
Study 11131368 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried onions and fresh cherry tomatoes meal
Number of subjects: 6
Study 9309996 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 40 ppm
Number of subjects: 9
Study 9309996 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at rest
Number of subjects: 9
Study 9309996 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) during exercise
Number of subjects: 9
Study 8346819 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (PHE) 2 micrograms/kg
Number of subjects: 16
Study 8346819 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE) 0.1 microgram/kg
Number of subjects: 16
Study 3518912 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (50 Gy)
Number of subjects: 494
Study 31740106 — intervention group
Group type: EXPERIMENTAL
Intervention: UP+tDCS
Number of subjects: 43
Study 31740106 — intervention group
Group type: EXPERIMENTAL
Intervention: UP
Number of subjects: 43
Study 28640990 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 37
Study 28640990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 28640990 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 37
Study 28824764 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom module (20-minute at-home video and 30 minutes of in-class case discussion)
Number of subjects: 73
Study 28824764 — intervention group
Group type: COMPARATOR
Intervention: Standard lecture (50-minute lecture from an expert educator)
Number of subjects: 73
Study 26584035 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir and asunaprevir
Number of subjects: 57
Study 26584035 — intervention group
Group type: COMPARATOR
Intervention: Simeprevir plus PEG‐IFN/RBV
Number of subjects: 57
Study 26584035 — intervention group
Group type: COMPARATOR
Intervention: Telaprevir plus PEG‐IFN/RBV
Number of subjects: 57
Study 24127448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vintafolide (2.5 mg IV three times per week during weeks 1 and 3) plus PLD (50 mg/m(2) IV once every 28 days)
Number of subjects: 149
Study 24127448 — intervention group
Group type: COMPARATOR
Intervention: PLD alone (50 mg/m(2) IV once every 28 days)
Number of subjects: 149
Study 24127448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vintafolide plus PLD in patients with 100% of lesions positive for FR
Number of subjects: 149
Study 24127448 — intervention group
Group type: COMPARATOR
Intervention: PLD alone in patients with 100% of lesions positive for FR
Number of subjects: 149
Study 24127448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vintafolide plus PLD in patients with FR-positive disease (10% to 90%)
Number of subjects: 149
Study 24127448 — intervention group
Group type: COMPARATOR
Intervention: PLD alone in patients with disease that did not express FR
Number of subjects: 149
Study 21437915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin/dexamethasone
Number of subjects: 20
Study 21437915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 20
Study 21437915 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin/polymyxin B/hydrocortisone
Number of subjects: 20
Study 21437915 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 18182447 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.8 mg/d
Number of subjects: 16
Study 18182447 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1.6 mg/d
Number of subjects: 16
Study 18182447 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg/d
Number of subjects: 16
Study 18182447 — intervention group
Group type: EXPERIMENTAL
Intervention: GH and DHEA (combination treatment)
Number of subjects: 16
Study 16687344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment (LLT) after CABG (group 1, n = 102, 49% male)
Number of subjects: 209
Study 16687344 — intervention group
Group type: COMPARATOR
Intervention: No lipid-lowering treatment (group 2, n = 107, 42% male)
Number of subjects: 209
Study 15313884 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 24535
Study 15313884 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 24535
Study 11024215 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (Angiotensin-Converting Enzyme Inhibitor)
Number of subjects: 75
Study 11024215 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB (Calcium Channel Blocker)
Number of subjects: 75
Study 11024215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9236507 — intervention group
Group type: EXPERIMENTAL
Intervention: Proventil HFA
Number of subjects: 20
Study 9236507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventolin
Number of subjects: 20
Study 9236507 — intervention group
Group type: EXPERIMENTAL
Intervention: Proventil
Number of subjects: 20
Study 9236507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8384096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 50
Study 8384096 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 50
Study 2869346 — intervention group
Group type: EXPERIMENTAL
Intervention: Entamoeba histolytica excretors
Number of subjects: 34